https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-03-01 / Int. J. Oncol. 2003 Mar;22(3):651-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-03-01 / Int. J. Oncol. 2003 Mar;22(3):651-62003-03-01 00:00:002019-02-15 09:23:52In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-03-01 / Lung Cancer 2003 Mar;39(3):339-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-03-01 / Lung Cancer 2003 Mar;39(3):339-452003-03-01 00:00:002003-03-01 00:00:00Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-03-01 / Int J Hyperthermia 2003 Mar-Apr;19(2):103-182003-03-01 00:00:002003-03-01 00:00:00The effect of whole-body hyperthermia combined with ‚metronomic‘ chemotherapy on rat mammary adenocarcinoma metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-62003-02-15 00:00:002019-02-15 08:50:31Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-212003-02-15 00:00:002020-06-23 09:42:47TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-06 / Cancer Immunol. Immunother. 2003 Mar;52(3):155-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-06 / Cancer Immunol. Immunother. 2003 Mar;52(3):155-612003-02-06 00:00:002019-02-15 09:13:27A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Expert Rev Anticancer Ther 2003 Feb;3(1):1-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Expert Rev Anticancer Ther 2003 Feb;3(1):1-32003-02-01 00:00:002019-02-15 08:44:50Dendritic cell therapy of cancer: can it fulfill its promise?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-52003-02-01 00:00:002019-02-15 09:19:55Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-632003-02-01 00:00:002019-02-15 08:50:30Fusions of breast cancer and dendritic cells as a novel cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-722003-02-01 00:00:002003-02-01 00:00:00HER2 dendritic cell vaccines
